<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>ODDA - Opioid Pain Medicine Prescribing Information Update</title>
    <link href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css" rel="stylesheet"/>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: Arial, sans-serif;
            background-color: #f5f5f5;
            line-height: 1.6;
        }

        /* Header */
        .header {
            background: linear-gradient(135deg, #2c3e50 0%, #34495e 100%);
            color: white;
            padding: 15px 20px;
            display: flex;
            justify-content: space-between;
            align-items: center;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.1);
        }

        .logo-section {
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .logo {
            width: 40px;
            height: 40px;
            background: linear-gradient(135deg, #3498db 0%, #2980b9 100%);
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-weight: bold;
            font-size: 14px;
        }

        .brand-text {
            display: flex;
            flex-direction: column;
        }

        .brand-name {
            font-size: 18px;
            font-weight: bold;
            margin: 0;
        }

        .brand-subtitle {
            font-size: 12px;
            color: #bdc3c7;
            margin: 0;
        }

        .menu-icon {
            font-size: 24px;
            cursor: pointer;
        }

        /* Navigation Breadcrumb */
        .nav-breadcrumb {
            background: white;
            padding: 15px 20px;
            border-bottom: 1px solid #e9ecef;
            font-size: 14px;
        }

        .nav-breadcrumb a {
            color: #3498db;
            text-decoration: none;
            margin-right: 5px;
        }

        .nav-breadcrumb a:hover {
            text-decoration: underline;
        }

        .nav-breadcrumb span {
            color: #6c757d;
            margin: 0 5px;
        }

        /* Main Content */
        .main-container {
            max-width: 1000px;
            margin: 0 auto;
            padding: 30px 20px;
        }

        .content-section {
            background: white;
            border-radius: 10px;
            padding: 30px;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.1);
            margin-bottom: 30px;
        }

        .page-title {
            font-size: 2em;
            color: #2c3e50;
            margin-bottom: 10px;
            text-align: center;
            border-bottom: 3px solid #e74c3c;
            padding-bottom: 15px;
        }

        .therapeutic-area {
            text-align: center;
            font-style: italic;
            color: #e74c3c;
            margin-bottom: 30px;
            font-size: 1.1em;
        }

        .section-title {
            font-size: 1.4em;
            color: #2c3e50;
            margin: 25px 0 15px 0;
            padding-bottom: 8px;
            border-bottom: 2px solid #3498db;
        }

        .highlight-box {
            background: #fff3cd;
            border: 1px solid #ffeaa7;
            border-left: 4px solid #f39c12;
            padding: 20px;
            margin: 20px 0;
            border-radius: 5px;
        }

        .warning-box {
            background: #f8d7da;
            border: 1px solid #f5c6cb;
            border-left: 4px solid #e74c3c;
            padding: 20px;
            margin: 20px 0;
            border-radius: 5px;
        }

        .info-box {
            background: #d1ecf1;
            border: 1px solid #bee5eb;
            border-left: 4px solid #3498db;
            padding: 20px;
            margin: 20px 0;
            border-radius: 5px;
        }

        ul {
            margin-left: 20px;
            margin-bottom: 15px;
        }

        li {
            margin-bottom: 8px;
        }

        .back-button {
            display: inline-block;
            background: #3498db;
            color: white;
            padding: 12px 24px;
            text-decoration: none;
            border-radius: 5px;
            margin-bottom: 20px;
            transition: background-color 0.3s;
        }

        .back-button:hover {
            background: #2980b9;
        }

        .footer {
            background: #2c3e50;
            color: white;
            padding: 20px;
            text-align: center;
            margin-top: 50px;
        }

        /* Responsive Design */
        @media (max-width: 768px) {
            .main-container {
                padding: 20px 15px;
            }
            
            .content-section {
                padding: 20px;
            }
            
            .page-title {
                font-size: 1.5em;
            }
        }
    </style>
</head>
<body>
    <!-- Header -->
    <header class="header">
        <div class="logo-section">
            <div class="logo">ODDA</div>
            <div class="brand-text">
                <h1 class="brand-name">ODDA</h1>
                <p class="brand-subtitle">Journey to FDA</p>
            </div>
        </div>
        <div class="menu-icon">
            <i class="fas fa-bars"></i>
        </div>
    </header>

    <!-- Navigation Breadcrumb -->
    <nav class="nav-breadcrumb">
        <a href="index.html"><i class="fas fa-home"></i> Home</a>
        <span>&gt;</span>
        <a href="index.html">Drug Safety Communications</a>
        <span>&gt;</span>
        <span>Opioid Pain Medicine Update</span>
    </nav>

    <!-- Main Content -->
    <main class="main-container">
        <a href="index.html" class="back-button">
            <i class="fas fa-arrow-left"></i> Back to Safety Communications
        </a>

        <div class="content-section">
            <h1 class="page-title">ODDA Requires Opioid Pain Medicine Manufacturers to Update Prescribing Information Regarding Long-Term Use</h1>
            <div class="therapeutic-area">Therapeutic Area: Pain Management</div>

            <div class="section-title">Safety Concern Announced</div>
            <div class="warning-box">
                <ul>
                    <li>In May 2025, ODDA reviewed new <strong>observational studies (PMRs 3033-1 and 3033-2)</strong> on long-term opioid therapy.</li>
                    <li>Findings showed <strong>increased risks</strong> of:
                        <ul>
                            <li>Misuse</li>
                            <li>Abuse</li>
                            <li>Addiction</li>
                            <li>Fatal & non-fatal overdose</li>
                        </ul>
                    </li>
                    <li>ODDA determined drug labeling must be updated to reflect these risks.</li>
                </ul>
            </div>

            <div class="section-title">What ODDA Is Doing (Labeling Updates)</div>
            <div class="info-box">
                <p><strong>Key changes required:</strong></p>
                <ul>
                    <li>Remove <strong>"extended treatment period"</strong> (misleading safety/efficacy assumption).</li>
                    <li>Emphasize:
                        <ul>
                            <li><strong>Higher doses = higher risks</strong>, persisting throughout therapy.</li>
                            <li><strong>New quantitative risk estimates</strong> from PMR studies.</li>
                        </ul>
                    </li>
                    <li>Clarify:
                        <ul>
                            <li>ER/LA opioids only when <strong>IR opioids are inadequate</strong>.</li>
                            <li>Avoid <strong>abrupt discontinuation</strong> (risk of withdrawal, uncontrolled pain, suicide).</li>
                        </ul>
                    </li>
                    <li>Add information about:
                        <ul>
                            <li><strong>Overdose reversal agents</strong> (naloxone, nalmefene).</li>
                            <li><strong>Drug interactions</strong> with CNS depressants including gabapentinoids.</li>
                            <li><strong>Toxic leukoencephalopathy</strong> in overdose settings.</li>
                            <li><strong>Opioid-induced esophageal dysfunction</strong> (GI warning).</li>
                        </ul>
                    </li>
                </ul>
            </div>

            <div class="section-title">Guidance for Health Care Professionals</div>
            <ul>
                <li>Use a <strong>multimodal approach</strong> to pain management.</li>
                <li>Start with <strong>lowest effective dose of IR opioids</strong> for shortest duration.</li>
                <li>Reserve ER/LA opioids only for <strong>severe, persistent pain</strong>.</li>
                <li>Regularly re-evaluate benefit-risk profile and monitor for <strong>misuse/addiction</strong>.</li>
                <li>Discuss overdose reversal options with all patients.</li>
                <li>Educate patients about risks of combining opioids with <strong>alcohol, benzodiazepines, or gabapentinoids</strong>.</li>
            </ul>

            <div class="section-title">Guidance for Patients & Caregivers</div>
            <div class="highlight-box">
                <ul>
                    <li><strong>Take opioids exactly as prescribed</strong> â€” never more often or at higher doses without consulting a doctor.</li>
                    <li>Store securely and <strong>do not share</strong> medicines.</li>
                    <li>Dispose of unused opioids at <strong>take-back sites</strong> or with prepaid mail-back envelopes.</li>
                    <li>Seek emergency help if signs of <strong>respiratory depression</strong> occur.</li>
                    <li>Learn about and access <strong>naloxone/nalmefene</strong> for overdose reversal.</li>
                    <li>Do not stop suddenly â€” tapering under medical supervision is necessary.</li>
                </ul>
            </div>

            <div class="section-title">ODDA Findings (PMR Study Results)</div>
            <ul>
                <li><strong>PMR 3033-1 (2017â€“2021):</strong>
                    <ul>
                        <li>~1â€“6% developed <strong>opioid addiction</strong> (DSM-5 OUD criteria).</li>
                        <li>~9% developed <strong>abuse</strong>.</li>
                        <li>~22% developed <strong>misuse</strong>.</li>
                        <li><strong>History of substance use disorder</strong> = strongest risk factor.</li>
                    </ul>
                </li>
                <li><strong>PMR 3033-2 (2006â€“2016):</strong>
                    <ul>
                        <li>5-year <strong>overdose incidence: 1.5â€“4%</strong>.</li>
                        <li>~17% of overdoses were <strong>fatal</strong>.</li>
                        <li>Higher baseline opioid dose = consistent overdose risk factor.</li>
                    </ul>
                </li>
            </ul>

            <div class="section-title">Facts About Opioid Pain Medicines</div>
            <ul>
                <li>Categories:
                    <ul>
                        <li><strong>Immediate-release (IR)</strong> -- every 4â€“6 hrs for acute pain.</li>
                        <li><strong>Extended-release/long-acting (ER/LA)</strong> -- once/twice daily for persistent severe pain.</li>
                    </ul>
                </li>
                <li>Forms: Tablets, capsules, lozenges, patches, sprays, injections.</li>
                <li>Side effects: Drowsiness, nausea, constipation, respiratory depression, dependence.</li>
                <li>Risk factors: Family/personal history of <strong>substance use disorder</strong> or mental illness.</li>
                <li>Overdose reversal: <strong>Naloxone (OTC & Rx)</strong>, <strong>Nalmefene (Rx)</strong>.</li>
            </ul>
        </div>
    </main>

    <!-- Footer -->
    <footer class="footer">
        <p>Â© 2025 ODDA. All rights reserved. | Contact: 1-888-INFO-ODDA</p>
    </footer>
</body>
</html>
